Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Employees - 117, CEO - Mr. Jaisim Shah, Sector - Healthcare, Country - US, Market Cap - 57.67M

Altman ZScore(max is 10): -13.09, Piotroski Score(max is 10): 5, Working Capital: $-218088000, Total Assets: $92953000, Retained Earnings: $-563052000, EBIT: -70845000, Total Liabilities: $285594000, Revenue: $56590000

- Current Price $0.24 - Analyst Target Price $12.81